Marie Maraninchi1, Nadège Padilla1, Sophie Béliard2, Bruno Berthet3, Juan-Patricio Nogueira4, Jeanine Dupont-Roussel1, Julien Mancini5, Audrey Bégu-Le Corroller6, Noémie Dubois6, Rachel Grangeot6, Catherine Mattei6, Marion Monclar6, Anastasia Calabrese6, Carole Guérin3, Charles Desmarchelier1, Alain Nicolay7, Changting Xiao8, Patrick Borel1, Gary F Lewis8, René Valéro9. 1. Aix-Marseille Univ, INSERM, INRA, NORT, Marseille, France. 2. Aix-Marseille Univ, INSERM, INRA, NORT, Marseille, France; Department of Nutrition, Metabolic Diseases, Endocrinology, CHU La Conception, APHM, Marseille, France. 3. Department of General and Endocrine Surgery, La Conception Hospital, APHM, Marseille, France. 4. Instituto Modelo de Gastroenterologia, Formosa, Argentina; Facultad de Ciencias de la Salud, Universidad Nacional de Formosa, Formosa, Argentina. 5. Aix-Marseille Univ, INSERM, IRD, UMR912, SESSTIM, Marseille, France; Public Health Department (BIOSTIC), Timone Hospital, APHM, Marseille, France. 6. Department of Nutrition, Metabolic Diseases, Endocrinology, CHU La Conception, APHM, Marseille, France. 7. Aix-Marseille Univ, INSERM, INRA, NORT, Marseille, France; Laboratory of Endocrine Biochemistry, La Conception Hospital, APHM, Marseille, France. 8. Department of Medicine and Physiology, Banting and Best Diabetes Centre, University of Toronto, Ontario, Canada. 9. Aix-Marseille Univ, INSERM, INRA, NORT, Marseille, France; Department of Nutrition, Metabolic Diseases, Endocrinology, CHU La Conception, APHM, Marseille, France. Electronic address: rvalero@mail.ap-hm.fr.
Abstract
BACKGROUND: Elevated apolipoprotein C-III (apoC-III) has been postulated to contribute to the atherogenic dyslipidemia seen in obesity and insulin-resistant states, mainly by impairing plasma triglyceride-rich lipoprotein (TRL) metabolism. Bariatric surgery is associated with improvements of several obesity-associated metabolic abnormalities, including a reduction in plasma triglycerides (TGs) and an increase in plasma high-density lipoprotein cholesterol (HDL-C). OBJECTIVES: We investigated the specific effect of bariatric surgery on apoC-III concentrations in plasma, non-HDL, and HDL fractions in relation to lipid profile parameters evolution. METHODS: A total of 132 obese subjects undergoing bariatric surgery, gastric bypass (n = 61) or sleeve gastrectomy (n = 71), were studied 1 month before surgery and 6 and 12 months after surgery. RESULTS: Plasma apoC-III, non-HDL-apoC-III, and HDL-apoC-III concentrations were markedly reduced after surgery and strongly associated with reduction in plasma TG. This decrease was accompanied by a redistribution of apoC-III from TRL to HDL fractions. In multivariate analysis, plasma apoC-III was the strongest predictor of TG reduction after surgery, and the increase of HDL-C was positively associated with plasma adiponectin and negatively with body mass index. CONCLUSION: Marked reduction of apoC-III and changes in its distribution between TRL and HDL consistent with a better lipid profile are achieved in obese patients after bariatric surgery. These apoC-III beneficial modifications may have implications in dyslipidemia improvement and contribute to cardiovascular risk reduction after surgery.
BACKGROUND: Elevated apolipoprotein C-III (apoC-III) has been postulated to contribute to the atherogenic dyslipidemia seen in obesity and insulin-resistant states, mainly by impairing plasma triglyceride-rich lipoprotein (TRL) metabolism. Bariatric surgery is associated with improvements of several obesity-associated metabolic abnormalities, including a reduction in plasma triglycerides (TGs) and an increase in plasma high-density lipoprotein cholesterol (HDL-C). OBJECTIVES: We investigated the specific effect of bariatric surgery on apoC-III concentrations in plasma, non-HDL, and HDL fractions in relation to lipid profile parameters evolution. METHODS: A total of 132 obese subjects undergoing bariatric surgery, gastric bypass (n = 61) or sleeve gastrectomy (n = 71), were studied 1 month before surgery and 6 and 12 months after surgery. RESULTS: Plasma apoC-III, non-HDL-apoC-III, and HDL-apoC-III concentrations were markedly reduced after surgery and strongly associated with reduction in plasma TG. This decrease was accompanied by a redistribution of apoC-III from TRL to HDL fractions. In multivariate analysis, plasma apoC-III was the strongest predictor of TG reduction after surgery, and the increase of HDL-C was positively associated with plasma adiponectin and negatively with body mass index. CONCLUSION: Marked reduction of apoC-III and changes in its distribution between TRL and HDL consistent with a better lipid profile are achieved in obesepatients after bariatric surgery. These apoC-III beneficial modifications may have implications in dyslipidemia improvement and contribute to cardiovascular risk reduction after surgery.
Authors: J M Gómez-Martin; J A Balsa; E Aracil; M Cuadrado-Ayuso; M Rosillo; G De la Peña; M A Lasunción; H F Escobar-Morreale; J I Botella-Carretero Journal: Lipids Health Dis Date: 2018-06-20 Impact factor: 3.876
Authors: Jonathan M Wilson; Amir Nikooienejad; Deborah A Robins; William C Roell; Jeffrey S Riesmeyer; Axel Haupt; Kevin L Duffin; Marja-Riitta Taskinen; Giacomo Ruotolo Journal: Diabetes Obes Metab Date: 2020-09-15 Impact factor: 6.577